Thelansis’s "MAC Lung Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential MAC Lung Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
MAC Lung Disease is a chronic nontuberculous mycobacterial infection with heterogeneous clinical progression, frequently occurring in patients with underlying structural lung abnormalities such as bronchiectasis or cavitary disease. Prolonged multidrug antimycobacterial therapy remains the foundation of treatment, typically incorporating a macrolide and ethambutol, with therapy generally continuing for at least 12 months after sputum culture conversion. However, treatment is associated with substantial pill burden, adverse effects, drug interactions, antimicrobial resistance, and microbiological relapse or treatment failure. For patients with refractory MAC Lung Disease who remain culture-positive after at least six months of guideline-based therapy, inhaled liposomal amikacin (ALIS) provides a targeted pulmonary-delivery option and is FDA-approved as part of combination therapy. The development landscape is now expanding beyond ALIS toward additional inhaled formulations, including Phase 3 inhaled clofazimine, as well as novel and repurposed antimycobacterial agents for refractory or drug-resistant disease. Key opportunities remain in improving localized drug exposure, shortening treatment duration, reducing toxicity, limiting resistance, and achieving more durable microbiological control.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest MAC Lung Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report
Our team will get in touch with you shortly about the MAC Lung Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report.